Chronic kidney disease (CKD) is a global public health challenge, projected to become the fifth highest cause of life-years lost by 2040. While CKD is traditionally managed through blood pressure control and dialysis, a growing body of evidence shows that gut microbiota and its metabolites actively contribute to CKD progression and its comorbidities.
In a recent commentary by Holle and Bartolomaeus, key findings from various CKD cohorts highlight the potential of gut-derived metabolites as both biomarkers and therapeutic targets, thus representing a critical step towards personalized and mechanism-driven nephrology.1
The Microbiome as a Source of Uremic Toxins
Since pediatric patients tend to have fewer comorbidities than adults, pediatric cohorts are uniquely suited to elucidating relevant microbiome-host interactions. Two key pediatric CKD studies, Chronic Kidney Disease in Children (CKiD) and Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C), demonstrate stage-dependent increases in gut-derived toxins, including indoxyl sulfate (IxS), p-cresyl sulfate (pCS), and phenylacetylglutamine (PAG). They also demonstrate disease-specific metabolic signatures, which are associated with vascular structure, neurocognitive development, and CKD progression.
Metabolomics at Scale: The Role of Metabolon
A foundational element of this research has been the application of Metabolon’s high-throughput, mass spectrometry-based metabolomics platform, which was used extensively in the CKiD study and German Chronic Kidney Disease (GCKD), an adult cohort study.
This platform enabled untargeted detection and annotation of over 1,400 plasma metabolites in adults and 622 in children with CKD, along with systematic profiling of longitudinal metabolome changes, and identification of metabolites associated with eGFR decline, neurocognitive development, and disease etiology.
The CKiD consortium leveraged this resource not only to explore novel biomarkers but also to develop machine learning classifiers capable of distinguishing CKD etiologies based on metabolic signatures. Importantly, targeted absolute quantification of gut-derived toxins (e.g., indoxyl sulfate, p-cresyl sulfate, phenylacetylglutamine) has since built on these untargeted data, to represent a crucial step towards offering practical tools for translational interpretation and clinical correlation.
Uremic Toxins: Byproducts of the Microbiome
The Metabolon platform helped reveal that many circulating uremic toxins are microbial in origin, originating from fermentation of dietary tryptophan, tyrosine, and phenylalanine. These are then conjugated by host enzymes and accumulate in CKD due to impaired renal clearance.
The CKiD and 4C studies found a CKD stage-dependent increase in microbial toxins, etiology-specific differences in metabolite accumulation, and diverging associations with clinical outcomes like cardiovascular phenotype and neurocognitive metrics. These observations were made possible through repeated, standardized metabolomic measurements, exemplifying how metabolomics data can anchor longitudinal observational studies in mechanistic biology.
Quantifying and Linking Metabolites to Outcomes
Targeted mass spectrometry now enables absolute quantification of microbial metabolites in pediatric plasma samples, which is a crucial step towards 1) gaining deeper mechanistic insight into pathways that are disrupted by CKD pathophysiology and 2) tying those mechanisms to the disease phenotype. Using targeted metabolomics to elucidate such mechanisms and to differentiate inter-individual variability beyond disease stage offers insight into tailored therapeutic strategies. There is a call for future research to focus on characterizing metabolomic profiles of subpopulations of CKD patients so that microbiome-targeted interventions can be matched to patients who might benefit from these treatments. Linking metabolic changes to clinical outcomes begins with untargeted metabolomics, which offers a high level view of the metabolome, and advances with targeted metabolomics, which allows special focus of pathways of interest.
Therapeutic Targeting: From Bench to Bedside
With evidence supporting the microbiome’s role in generating uremic toxins, modulating gut microbial composition or function has become a therapeutic goal.
Prebiotic and probiotic interventions—particularly fiber-based strategies like inulin—have shown promising results in animal models. However, translating these findings to human CKD has proven challenging. Pilot trials show microbiome compositional changes without consistent reductions in toxin levels, underscoring the complexity of host-microbe-metabolite interactions.
Advancing microbiome-targeted therapies in CKD will require stratification of patient subgroups based on microbiome and metabolome profiles, consideration of environmental covariates (diet, antibiotics, physical activity), and predictive modeling of metabolite production using systems biology and machine learning. In pediatrics, the relative absence of frailty and multimorbidity may enhance treatment efficacy and signal clarity, making this an ideal setting for early-phase trials. Furthermore, scalable, cost-effective microbiome diagnostics and validated metabolite assays are essential to operationalize this approach in clinical nephrology.
Final Considerations
The evolving understanding of the gut-kidney axis is redefining how we conceptualize and manage CKD. As we continue to dissect the pathophysiological relevance of gut-derived toxins and test interventions that target microbial pathways, precision nephrology must extend beyond the genome—to include the metabolome and microbiome.
For clinician-scientists, this represents both a challenge and an opportunity: to bridge mechanistic insight with therapeutic innovation, and to leverage pediatric models to inform broader clinical practice.
References
1. Holle, J. and H. Bartolomaeus, Gut-derived metabolites as treatment targets in chronic kidney disease-an avenue toward personalized medicine. Pediatr Nephrol, 2025. 40(5): p. 1505-1510
